Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1625288/000149315220005890/form8-k.htm
January 2022
July 2020
October 2019
July 2019
April 2019
March 2019
March 2019
March 2019
Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1625288/000149315220005890/form8-k.htm
Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Nexien Biopharma, Inc..
Nexien Biopharma, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:
Ticker: NXENEvents:
CIK: 1625288
Form Type: 8-K Corporate News
Accession Number: 0001493152-20-005890
Submitted to the SEC: Mon Apr 06 2020 3:04:45 PM EST
Accepted by the SEC: Mon Apr 06 2020
Period: Tuesday, March 31, 2020
Industry: Pharmaceutical Preparations